Latest / Bloomberg Intelligence
Moderna and Merck Revive mRNA Hopes With Melanoma Success
Watch Paul and Scarlet LIVE every day on YouTube: http://bit.ly/3vTiACF.
Bloomberg Intelligence hosted by Paul Sweeney and Judy Lagrou
- Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the latest in the biotech sector. A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer. The trial met its main goal as the vaccine, combined with Merck’s immune drug Keytruda, prevented…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.